SPIA
LOGC

Steward Partners Investment Advisory’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Steward Partners Investment Advisory’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-300
Closed -$2.18K – 7531
2021
Q1 		$2.18K Buy
+300
New +$2.47K ﹤0.01% 3214

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Steward Partners Investment Advisory's LOGC Position: Q2 2021 in Review

Steward Partners Investment Advisory sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2021, closing a stake of 300 shares — an estimated $2.18K sold.

Steward Partners Investment Advisory first reported a position in LOGC in Q1 2021 and held it in 1 quarter. The position peaked at $2.18K in Q1 2021. 63 funds tracked by Wall St. Rank hold LOGC as of Q2 2021.

  • Steward Partners Investment Advisory reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 300 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $2.18K.
  • Steward Partners Investment Advisory first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Steward Partners Investment Advisory's LogicBio Therapeutics, Inc. Common Stock position peaked at $2.18K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2021, filed 13 Aug 2021.